Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have received a consensus recommendation of “Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $27.33.
A number of research analysts recently weighed in on the company. BidaskClub downgraded Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Jefferies Financial Group assumed coverage on Kalvista Pharmaceuticals in a research note on Tuesday, October 30th. They set a “buy” rating and a $30.00 price target on the stock. Stifel Nicolaus assumed coverage on Kalvista Pharmaceuticals in a research note on Monday, October 15th. They set a “buy” rating on the stock. Cantor Fitzgerald set a $32.00 price target on Kalvista Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. Finally, Zacks Investment Research downgraded Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a research note on Thursday, September 20th.
KALV stock opened at $18.82 on Friday. Kalvista Pharmaceuticals has a fifty-two week low of $7.73 and a fifty-two week high of $23.97. The company has a market cap of $316.09 million, a P/E ratio of -12.30 and a beta of 2.87.
In other news, Director Albert Cha purchased 1,058,824 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average cost of $17.00 per share, with a total value of $18,000,008.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 49.10% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Interwest Venture Management Co. increased its holdings in Kalvista Pharmaceuticals by 17.8% during the 3rd quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock worth $8,596,000 after purchasing an additional 58,824 shares in the last quarter. Acuta Capital Partners LLC bought a new stake in Kalvista Pharmaceuticals during the 3rd quarter worth approximately $2,849,000. Wedge Capital Management L L P NC bought a new stake in Kalvista Pharmaceuticals during the 3rd quarter worth approximately $1,492,000. Stanley Laman Group Ltd. increased its holdings in Kalvista Pharmaceuticals by 48.3% during the 2nd quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 21,861 shares in the last quarter. Finally, EAM Investors LLC bought a new stake in Kalvista Pharmaceuticals during the 3rd quarter worth approximately $926,000. 37.12% of the stock is owned by hedge funds and other institutional investors.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
See Also: What is the balance sheet?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.